Indivior's Sublocade MAT to compete with Alkermes’ Vivitrol

FDA approved once-monthly subcutaneous Sublocade buprenorphine (RBP-6000) from Indivior plc (LSE:INDV) to treat opioid use disorder. The company said it expects to launch the drug next quarter at a wholesale

Read the full 307 word article

User Sign In